Iovance Biotherapeutics Inc (STU:2LB)
€ 10.415 0.26 (2.56%) Market Cap: 3.20 Bil Enterprise Value: 2.89 Bil PE Ratio: 0 PB Ratio: 4.43 GF Score: 39/100

Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript

Jun 08, 2020 / 03:00PM GMT
Release Date Price: €27.76 (+0.87%)
Iain D. Dukes
Iovance Biotherapeutics, Inc. - Chairman of the Board

Good morning. Will the meeting please come to order. My name is Iain Dukes, and I am the Chairman of the Board of Directors of Iovance Biotherapeutics, Inc. I'm pleased to welcome all of you to this annual meeting of the stockholders of Iovance Biotherapeutics.

In light of the public health impact of the coronavirus outbreak and in order to help protect the health and well-being of our shareholders and employees, this meeting is being held virtually through a live webcast. I would like to introduce you to Iovance directors and officers who are attending today's meeting: Maria Fardis; Athena Countouriotis; Ryan Maynard; Merrill A. McPeak; Wayne P. Rothbaum; and Michael Weiser are all directors of the company. Dr. Fardis is also the company's President and Chief Executive Officer.

Two of our other officers, Timothy Morris, our Chief Financial Officer; and Fred Vogt, our General Counsel, are also in attendance. Also present is Alan Markowitz, a representative of Marcum LLP, the company's independent registered public

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot